drugset / Trial / NCT01750580
Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To assess the safety and tolerability, characterize the dose-limiting toxicities (DLTs), and identify the maximally tolerated dose (MTD) of BMS-986015 given in combination with ipilimumab in subjects with select advanced (metastatic and/or unresectable) solid tumors.
Timeline
- Start
- 2012-12
- Primary completion
- 2015-04
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lirilumab | Monoclonal antibody | — | — |
| Background | Ipilimumab | Monoclonal antibody | — | — |
Indications
No indication recorded.